{
    "symbol": "IONS",
    "quarter": 4,
    "year": 2022,
    "date": "2023-02-22 14:57:05",
    "content": " And then we work very closely with R&D, as I said, integrating kind of our early-stage pipeline as well to understand kind of what indication strategy look like and how we want to think about going to market with that for ourselves and where we think there's more benefit for partners to actually again, realize the full potential of the product. What I can tell you is that we will focus the pipeline as we have done over the last couple of years when we announced and we said we're moving away from indications like oncology for example, which we moved away from because we don't think that that's the best use of our resources."
}